In another study, MDM2 inhibitors combined with anti-PD-1 antibodies in melanoma-bearing mice resulted in improved survival and fewer lung metastases compared with the treatment of MDM2 inhibitors alone. The gene discussed is MDM2; the disease is melanoma.